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Abstract
Astrocytes isolated from individuals with amyotrophic lateral sclerosis (ALS) are toxic towards 
motor neurons (MNs) and play a non-cell autonomous role in disease pathogenesis. The 
mechanisms underlying the susceptibility of motor neurons to cell death remains unclear. Here, we 
report that astrocytes derived from mice bearing ALS mutations and from individuals with ALS 
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reduce expression of major histocompatibility complex class I (MHCI) on MNs. Reduced MHCI 
expression makes these MNs susceptible to astrocyte-induced cell death. Increasing MHCI 
expression on MNs increases survival and motor performance in a mouse model of ALS and 
protects MN against astrocyte toxicity. A single MHCI molecule, HLA-F, protects MNs from ALS 
astrocyte-mediated toxicity, while knockdown of its receptor, the killer cell immunoglobulin-like 
receptor KIR3DL2, an inhibitory receptor that recognizes MHCI, on astrocytes results in enhanced 
MN death. These data indicate that in ALS upon loss of MHCI expression MNs become 
vulnerable to astrocyte-mediated toxicity.
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal, adult onset neurodegenerative disorder 
characterized by the progressive loss of motor neurons (MNs) and death due to respiratory 
failure1. The majority of cases are classified as sporadic ALS (SALS), defined as having no 
family history of the disease. Despite efforts to identify risk factors and potential 
susceptibility genes, the etiology of SALS remains largely unknown2. Current understanding 
of cellular and molecular mechanisms underlying this disease is mostly derived from 
animals models bearing mutations in genes associated with autosomal dominant familial 
ALS (FALS)3-7. Despite the difference in etiology, FALS and SALS are phenotypically 
indistinguishable. Several studies suggest a common disease mechanism underlying FALS 
and SALS8,9 and therefore knowledge gathered from animal models of FALS can help 
understand the mechanism behind SALS10.
In addition to cell intrinsic damage occurring within MNs, glial cells such as astrocytes, 
microglia and oligodendrocytes contribute to MN death in ALS in a non-cell autonomous 
manner
11
,
12
. Astrocytes derived from postmortem biopsies of human ALS individuals 
induce MN death in vitro, opening the possibility to study these patient specific cells in great 
detail13,14. However, the understanding of how and why MNs die in this disease remains 
unknown.
Recent work in development, aging and neurological disorders, including ALS has focused 
on immune molecules, such as cytokines, proteins of the complement system, and major 
histocompatibility complex class I (MHCI) proteins and their role in the developing and 
adult brain15-17. In the central nervous system (CNS), MHCI plays a role in synaptic 
function15,18-22, and in neurodegenerative processes23,24. In the ALS mouse model, which 
express a disease-associated variant in superoxide dismutase 1 (SOD1G93A) mice, higher 
levels of MHCI in MNs were found in animals that presented a slower disease 
progression25. Furthermore, disease progression is accelerated in SOD1G93A mice lacking 
beta-2 microglobulin (?2m), an essential component for MHCI presentation26. Taken 
together these findings suggest that MHCI may have a role in the pathogenesis of ALS.
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Results
MHCI expression is reduced on MNs in ALS
MHCI molecules and ?2m are enriched in mouse spinal MNs (Supplementary Fig. 1a,b). 
In order to examine changes in MHCI expression in MNs in ALS, we analyzed MHCI 
expression prior to and after disease onset in all segments of the spinal cord of SOD1G93A 
mice and compared them to wild-type mice. Using an antibody that recognizes subgroups of 
mouse MHCI (histocompatibility 2 (H2), kb and db) and commonly used for MHCI 
detection in MNs25,27, we found that MHCI expression was markedly reduced in MN 
somata but increased in motor axons in SOD1G93A mice after disease onset (Fig. 1a,b and 
Supplementary Fig. 1c-e). These results are in agreement with previous findings using 
another rapid progressing SOD1 mouse model (129Sv-SOD1G93A) showing that MHCI 
protein is transported away from MN cell body and accumulates in peripheral motor axons 
during disease progression25.
Next, to determine if loss of MHCI in MNs seen in the mouse model was also seen in human 
ALS individuals, we evaluated MHCI expression by immunohistochemistry in spinal cord 
samples from FALS carrying the SOD1A4V mutation and sporadic ALS individuals 
compared to non-ALS controls. Using an antibody recognizing human leukocyte antigen 
(HLA)-A, -B, and –C, we observed that MHCI expression in MNs was nearly absent in both 
FALS and SALS spinal cords as compared to MHCI levels expression in MNs of non-ALS 
samples (Fig. 1c,d).
Loss of MHCI by MNs after exposure to ALS astrocytes
Using our recently described co-culture system of adult CNS derived microglia with MNs28, 
we evaluated the impact of ALS microglia on the expression of MHCI in MNs. Although 
SOD1G93A microglia have been shown to be toxic to MNs28, when MNs were co-cultured 
with SOD1G93A microglia, no overt changes were observed in their MHCI expression (Fig. 
2a). By contrast when MNs were co-cultured with ALS astrocytes29, confirmed to be devoid 
of other glia types or cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells 
(Supplementary Fig. 2a-g), MHCI expression in MNs was diminished already within 24 
hours and steadily declined over the next 96 hours, at which point approximately 73% of 
MNs completely lost MHCI expression (Fig. 2b). MHCI expression in MNs was slightly 
increased during the same period when MNs were cultured on top of wild-type astrocytes 
(Fig. 2b). This could reflect MN maturation in the presence of astrocytes30, which affects 
MHCI expression patterns in neurons31.
In order to evaluate if expression of ALS linked-mutant SOD1 protein within MNs could 
lead to intrinsic down-regulation of MHCI expression, we generated wild-type and 
SOD1G93A MNs using induced pluripotent stem cell (iPSC) technology32. The iPSCs 
generated contained the green fluorescent protein (GFP) under the control of the MN 
specific Hb9 promoter allowing MN enrichment using a fluorescence activated cell sorter 
upon MN induced cell differentiation (Supplementary Fig. 3a-b)32. Upon confirming that 
both wild-type and SOD1G93A iPSC showed neuronal morphology and gene expression 
profiles similar to MNs derived from mouse embryonic stem cells (Supplementary Fig. 3c), 
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MHCI levels were evaluated. During the first 72 hours, no significant change in MHCI 
expression was found between wild-type and SOD1G93A MNs and only a modest down-
regulation of MHCI was observed in SOD1G93A MNs by 120 hour (Supplementary Fig. 
4a). A further decrease was not observed if SOD1G93A expressing MNs were culture in the 
presence of SOD1G93A astrocytes (Supplementary Fig. 4b), suggesting that ALS astrocytes 
act as a main contributor to the down-regulation of MHCI observed in MNs. Of note, the 
findings described above were not observed in GABAergic neurons, a neuronal population 
spared from ALS astrocyte induced toxicity when co-cultured 13,14,33,34, since MHCI 
expression levels in these cells were found to remained constant throughout the culture 
period in the presence of SOD1G93A astrocytes (Supplementary Fig. 4c).
Next, in order to determine if cell-cell contact between MNs and astrocytes was required for 
MHCI loss in MNs to occur, we cultured MNs in medium previously used to culture 
astrocytes but without physical contact with astrocytes. As observed in the presence 
SOD1G93A astrocytes by 24 hours majority of MNs lost MHCI expression after culture with 
SOD1G93A astrocyte conditioned medium a time point were at least 95% of MNs are still 
alive (Supplementary Fig. 5a), suggesting ALS astrocytes secrete factors that induce MHCI 
down-regulation in MNs. Based on these findings we then evaluated if we could recapitulate 
this down-regulation of MHCI in MNs observed in the presence of SOD1G93A astrocyte 
conditioned medium by using compounds acting on pathways shown to be affected in ALS. 
Compounds causing endoplasmic reticulum (ER) stress, oxidative stress, and inflammatory 
response were tested. Thapsigargin, a sarco-endoplasmic reticulum calcium ATPase 
inhibitor, known to induce ER stress in MNs35, led to loss of MHCI expression in more than 
76% of MNs, where menadione, an oxidative stress inducer, and the pro-inflammatory 
molecules, tumor necrosis factor (TNF?), interferon gamma (IFN?) and interleukin 2 (IL2) 
showed no or only moderate effects on MNs MHCI levels (Supplementary Fig. 5b). Taken 
together, these results suggest that astrocytes may secrete inducers of ER stress resulting in 
loss of MHCI in MNs.
Levels of MHCI in MN determine susceptibility to ALS astrocyte-induced toxicity
To test the hypothesis that restoring MHCI expression to MNs may prevent astrocyte 
mediated toxicity, we overexpressed three MHCI molecules in MNs prior to co-culture with 
mouse ALS astrocytes. Mouse classical MHCI of the subclasses H2db, H2kb or H2ld were 
overexpressed via lentiviral vectors in Hb9:GFP sorted MNs, resulting in transduction of 
more than 80% of MNs and rescue of MHCI levels on MNs exposed to SOD1G93A astrocyte 
(Supplementary Fig. 6a-d)36. While overexpression of H2db or H2ld in MNs resulted in a 
modest increase in MN survival, overexpression of H2kb fully protected MN from the toxic 
effects of SOD1G93A astrocytes with no changes in cell morphology (Fig. 3a). This effect 
was not due to the lentivirus infection per se since expression of RFP did not alter 
SOD1G93A astrocyte-mediated toxicity, with more than 60% of MNs dying within 120 hours 
of co-culture (Fig. 3b).
Knockdown of H2kb expression in MN did not induce MN cell death per se or alter their 
susceptibility to stress molecules (Supplementary Fig. 7a), but upon co-culture with 
SOD1G93A astrocytes increased susceptibility to SOD1G93A astrocyte-induced toxicity 
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(Supplementary Fig. 7b). Importantly, reduction of MHC I expression in GABAergic 
neurons lead to decreased survival upon co-culture with SOD1G93A astrocytes, with an 
observed 43.7% cell death as compared to scrambled shRNA transduced GABAergic 
neurons (Supplementary Fig. 7c-e). These findings suggest that MHCI expression by 
neuronal cells modulates their susceptibility to ALS astrocyte-induced toxicity.
Sustained H2k expression delayed SOD1 disease progression
Since AAV9 readily transduces MNs in the spinal cord when delivered in to the cerebral 
spinal fluid (CSF)37,38, we constructed AAV9 vectors to target MNs in SOD1G93A mice with 
H2kb (AAV9-H2k) or H2db (AAV9-H2d). We also used AAV9-GFP to confirm that high 
level of transduction in spinal cord MNs of SOD1G93A mice could be achieved by our 
delivery method (Supplementary Fig. 8a). AAV9-H2k (or AAV9-H2k) increased H2kb (or 
H2db) mRNA expression levels in spinal cords (Supplementary Fig. 8b). Expression of 
H2kb in MNs via AAV9 delivery starting at post-natal day 1 resulted in a 21-day extension 
in the mean survival SOD1G93A mice as compared to control (AAV9-empty) littermates 
(156.9 ± 2.6 days in AAV9-H2k versus 135.5 ± 1.6 days in AAV9-empty (Fig. 3c). Amongst 
AAV9-H2k injected animals, 39% of the animals survived over 165 days, with the longest 
living mouse reaching 182 days. When AAV9-H2k was delivered to SOD1G93A mice, no 
significant (P> 0.05) changes in mean survival were observed (139.2 ± 1.4 days in AAV9-
H2k versus 135.5 ± 1.6 days in AAV9-empty). Mean disease onset, as assessed by age at 
peak body weight did not differ between AAV9-H2k, AAV9-H2k and AAV9-empty groups 
(103.3 ± 2.0, 103.1 ± 1.2 and 99.73 ± 1.2 days, respectively; Fig. 3d-e). However, disease 
duration, assessed by disease progression, was increased by 50.3% in AAV9-H2k treated 
mice, but not in AAV9-H2k treated mice (Fig. 3f). Videos taken of SOD1G93A mice during 
the disease progression period, show a marked difference between AAV9-H2k injected 
versus AAV9-empty injected mice (Supplementary Videos 1-4). During this stage, AAV9-
H2k injected SOD1G93A mice showed greater ambulatory capacity compared to AAV9-
empty injected animals. Motor function was also improved as assessed by rotarod test (Fig. 
3g). The delay in disease progression observed when SOD1G93A mice were treated with 
AAV9-H2k is likely not derived from H2kb expression in astrocytes since the overexpression 
of H2kb in SOD1G93A astrocytes in vitro did not modify their toxicity towards MNs 
(Supplementary Fig. 9).
ALS astrocytes express MHCI inhibitory receptors
The levels of MHCI expression helps innate immune cells, including natural killer (NK) 
cells, to distinguish target cells from healthy cells39. Reduced presentation of MHCI antigen 
on target cells acts as a trigger for cytotoxic T lymphocytes (CTLs) to secrete effector 
molecules and kill the target cells40. However, when target cells retain MHCI expression, 
CTLs can sense this MHCI leading to the engagement of signaling cascades that inhibit 
lymphocytic toxicity and result in the preservation of target cells40,41. To determine if ALS 
astrocytes have the ability to sense MHCI levels on MNs, we examined expression of MHCI 
receptors in astrocytes. mRNA expression of H2k inhibitory receptors of the Ly49 family 
such Ly49c, Ly49i and Ly49w were highly expressed SOD1G93A mice at end stages of 
disease (Fig. 4a). Immunostaining analysis using antibodies to detect Ly49c and Ly49i 
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(Ly49c/i) receptors confirmed expression of these two receptors in the ventral horn of the 
lumbar spinal cord of SOD1G93A mice, with little to no expression in age-matched wild-type 
mice (Fig. 4b-c). 96 ± 2% of Ly49c/i positive cells were astrocytes (defined by 
immunoreactivity to the astrocyte specific membrane protein GLAST or the cytoplasmic 
protein GFAP) (Fig. 4c and Supplementary Fig. 10a). Ly49c/i receptors were also 
expressed in SOD1G93A astrocytes used in our in vitro studies (Fig. 4d-e). These receptors 
were also detected in infiltrating CTLs found in the spinal cord of SOD1G93A mice42, 
however CTL numbers were minimal and therefore only accounted for a small fraction of 
cells expressing Ly49c/i receptors (Supplementary Fig. 10b).
We extended our analysis to astrocytes derived from individuals with ALS and analyzed 
mRNA expression of a wide panel of 14 MHCI receptors. Killer cell immunoglobulin-like 
receptor 3DL2 (KIR3DL2), an inhibitory MHCI receptor, was uniquely expressed in all 
human ALS astrocyte cell lines tested (Fig. 4f). There was no detectable expression of 
MHCI inhibitory receptor, including KIR3DL2 or any other KIR in non-ALS control 
astrocyte cell lines tested. Expression of KIR3DL2 was also confirmed in post-mortem 
spinal cord samples of SALS individuals, where KIR3DL2 expression was predominantly 
localized to GFAP positive astrocytes (Fig. 4g-h).
HLA-F protects human MNs from ALS astrocyte toxicity
Major histocompatibility complex, class I, F (HLA-F), a human MHCI molecule, has been 
identified as a ligand that can physically and functionally interact with the KIR3DL2 
receptor43. HLA-F is expressed in MNs of non-ALS spinal cord samples, and its expression 
is reduced in ALS MNs (Fig. 5a-b). To test whether sustained expression of HLA-F in 
human MNs protects them from ALS astrocyte induced toxicity, we used an in vitro model 
system where human MNs and human astrocytes were co-cultured14. MNs were generated 
from human embryonic stem cells and found to exhibit good neuronal morphology, 
expression of the MN markers homeobox gene (HB9), neurofilament marker (SMI32) and 
choline acetyltransferase (ChAT) and minimal to none non-neuronal cell contamination (Fig. 
5c). Given that MHCI recognition is species specific, we needed to construct a vector that 
could deliver HLA-F to human MNs. A lentiviral vector encoding human HLA-F cDNA 
along with an IRES and eGFP (Lv-HLAF-IRES-eGFP) to track transduced cells was 
produced. Transgene expression and high levels of MN transduction were confirmed, with a 
transduction efficiency of over 90% (Fig. 5d), and all cells expressing eGFP were found to 
express HLA-F (Supplementary Fig. 11). Three-days after the MNs were transduced with 
Lv-HLAF-IRES-eGFP, astrocytes devoid of contamination by other glia and CTLs, 
(Supplementary Fig. 2d,e) were added to cultures. After 2 weeks of co-culture we observed 
that overexpression of HLA-F in human derived MNs increased their survival upon co-
culture with either FALS or SALS astrocytes (Fig. 5e-f). No change in MN survival was 
observed when MNs overexpressing HLA-F were co-cultured with non-ALS astrocytes, 
suggesting a specific effect of HLA-F in preventing ALS astrocyte mediated toxicity rather 
than improved general MN survival. To test whether suppression of KIR3DL2 in ALS 
astrocytes will enhance their toxicity towards MNs, we reduced KIR3DL2 expression in 
human astrocytes using shRNA directed against KIR3DL2 (Supplementary Fig. 12a). All 
ALS astrocytes treated with scrambled shRNA were toxic to MNs, with approximate 50% 
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MNs death observed by day 14 (Supplementary Fig. 12b). When the same MNs were co-
cultured with ALS astrocytes lacking KIR3DL2 expression, 50% MN death could already be 
observed by day 7 of co-culture (Supplementary Fig.12b) suggesting an increase cell death 
activity of ALS astrocytes if they lack the functional interacting domain to HLA-F.
Discussion
We and others have recently shown that astrocytes derived from individuals with ALS are 
toxic to MNs13,14,44. These findings add to the growing evidence that non-cell autonomous 
mechanisms contribute to MN death in ALS, and point to a crucial role of glia in ALS 
pathogenesis11,12. However the mechanisms behind ALS astrocyte toxicity and selectivity 
towards MNs remain unknown. The understanding of these mechanisms is required to 
develop therapies aiming at delaying or even preventing MN degeneration in ALS. Our 
findings reported here show that ALS astrocytes recognize MNs as their targets based on the 
reduced expression of MHCI observed in MNs at later stages of disease in SOD1G93A 
mouse model as well in ALS autopsy material. The relatively stable levels of MHCI found in 
GABAergic neurons upon culture with ALS astrocytes helps explain why certain neuronal 
subtypes other than MNs are spared from the astrocyte toxicity. Interestingly, in ALS 
microglia do not cause down-regulation of MHCI in MNs, but still induce MN death28, 
suggesting that the mechanisms for MN recognition by reduced level of MHCI are astrocyte 
specific within the glial population. Overall, along with previous reports suggesting possible 
involvement of MHCI in many neurologic disorders23-25,45-47, our findings support the 
important role of MHCI molecules in the motor neuron degeneration occurring in ALS.
Further studies are necessary to precisely identify signals originating from the astrocytes and 
the molecular mechanism behind MHCI reduction in MNs upon contact with ALS 
astrocytes. Here, we showed soluble factors secreted from ALS astrocytes can down-regulate 
MN MHCI expression, and identify ER stress as a likely mechanism governing this down-
regulation. ER dysfunction is a critical contributor to MHCI loss on various cell types48. 
Indeed, in the SOD1 mouse models, ER stress is one of the first phenotypic alterations 
detected in vulnerable MNs49,50, and remains a prominent feature of post-mortem ALS 
subject spinal cord MNs51. Since down-regulation of MHCI may initiate cellular events to 
trigger ALS astrocyte toxicity, it is imperative to identify how ALS astrocytes cause ER 
stress in MNs. Among the potential candidates, misfolded SOD1 should be considered due 
to their known involvements towards ER stress35,52.
Our results are in alignment with the finding that ALS astrocytes might develop aberrant 
characteristics to convey toxicity to MNs53. Despite this, the observation that FALS and 
SALS astrocytes express predominantly a single killer cell immunoglobulin-like receptor, 
KIR3DL2, opens the possibility to find common molecules that have potential therapeutic 
strategy to ALS despite disease etiology. Due to its ability to interact with KIR3DL2 43, and 
the low frequency of polymorphisms among different human populations54, HLA-F is a 
promising candidate. Strikingly, HLA-F protein expression was found to be down regulated 
in post-mortem samples of ALS spinal cord MNs, and sustained HLA-F expression in 
human MNs in vitro confers protection from both FALS and SALS astrocyte toxicity. These 
findings suggest viral vectors, such as AAVs that may be developed to treat CNS 
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disorders55-59 in order to deliver HLA-F to MNs and hamper astrocyte toxicity in the larger 
body of SALS individuals.
Online Methods
Animals
All procedures were performed in accordance with the NIH Guidelines on the care and use 
of vertebrate animals and approved by the Institutional Animal Care and Use Committee of 
the Research Institute at Nationwide Children's Hospital. Transgenic mice that expressed 
human SOD1 carrying the G93A mutation (B6SJL-TgSOD1G93A), referred to here as 
SOD1G93A mice, were obtained from Jackson Laboratories and maintained, characterized by 
the guidelines of Jackson Laboratory for the entire of animal study60 (Bar Harbor, ME). 
Animals were bred at our facilities and were housed under light/dark (12:12 hour) cycle with 
food and water ad libitum. At each generation, animals were genotyped, SOD1G93A 
transgene copy number were verified by quantitative PCR, prior to either the isolation of 
primary cells or the injection of AAV9. To minimize variability due to gender effects on 
survival and behavior analysis, only female mice were used for AAV9-H2k injection 
experiments. After genotyping, SOD1G93A animals were randomly selected for AAV9 
injections of control, H2k or H2k. In each litter, half of the animals were treated with AAV9-
empty and half with AAV9-H2k or AAV9-H2k. All procedures were performed in 
accordance with the NIH Guidelines and were approved by the Nationwide Children's 
Research Institutional Animal Care and Use Committee. The numbers of mice used in each 
experiment varied are indicated in the figure legends.
SOD1G93A mouse survival and behavioral analysis
Disease stages (previously described28,57) included the following: “Pre-symptomatic stage,” 
during which mice displayed no disease symptoms and were not yet at peak body weight; 
“Symptomatic-stage,” during which mice showed overt symptoms characterized by tremors 
and hindlimb paralysis and showed a 10% or more decrease from the peak of body weight; 
“End-stage,” during which animals exhibited forelimb and hindlimb paralysis and were 
unable to right themselves within 30 seconds after being placed on its back. “Disease onset” 
was defined as the age at which mice reach their peak body weight. “Disease progression” 
was defined as the time period between disease onset and end stage. Motor coordination was 
recorded using a rotarod instrument (Columbus Instruments, Columbus, OH), Three trials 
were performed on accelerating rotarod beginning at 5 rpm per minute twice a week. The 
time each mouse remained on the rod was recorded. Data collection and analysis was 
performed by a researcher that was blinded to the treatment of animal groups.
Isolation and culture of mouse glial cells
Astrocytes and microglia were isolated from 110-130 day old SOD1G93A and wild-type 
B6SJL mice. Astrocyte cultures were prepared as previously described with minor 
modifications61. Briefly, spinal cords were enzymatically dissociated to single cells with a 
mixture of Papain (2.5 U/ml; Worthington Biochemical, Lakewood, NJ), Dispase grade II (1 
U/ml; Boehringer Mannheim Corporation, Indianapolis, IN) and Dnase I (250 U/ml; 
Worthington Biochemical) for about 20 minutes. After filtration with a 70 μm nylon mesh, 
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cells were pelleted, and resuspended in DMEM/F12 (Invitrogen, Carlsbad, CA) which was 
supplemented with 10% fetal bovine serum (FBS, Invitrogen) and 0.2% N2 supplement 
(Invitrogen). The cells were then plated onto laminin coated 75 cm2 tissue culture flasks. 
Upon confluence, flasks were shaken overnight in order to remove potential microglial cells 
and then were treated with cytosine arabinose (20 μM, Sigma-Aldrich, St. Louis, MO). Prior 
to use, astrocyte preparations were screened for the presence of CTLs and natural killer 
(NK) cells and were found to be devoid of them.
Microglia were isolated following a protocol previously described28. Briefly, tissues were 
fragmented with a scalpel and incubated in enzymatic solution containing papain (2.5 U/ml; 
Worthington Biochemical) for 60 minutes at 37 °C. 20% FBS in Hank's Balanced Salt 
Solution (HBSS, Invitrogen) was applied to the tissue, and they were then centrifuged at 
200×g for 4 minutes. Cell pellets were resuspended in 2 ml of DNase I (0.5 mg/ml, 
Worthington Biochemical) in HBSS and were incubated for 5 minutes at room temperature. 
Tissue was gently disrupted with fire-polished Pasteur pipettes, filtered through a 70 micron 
cell strainer, and centrifuged at 200×g for 4 minutes. Pellet was then resuspended in 20ml of 
20% isotonic Percoll (GE healthcare) in HBSS. 20ml of pure HBSS was carefully laid on 
top the percoll layer and centrifugation was performed at 200×g for 20 minutes with slow 
acceleration and no brake. The pellet containing the mixed glial cell population was washed 
once with HBSS and was suspended in Dulbecco's modified Eagle's/F12 medium with 
GlutaMAX™ (DMEM/F12, Invitrogen) supplemented with 10% heat inactivated FBS, 
antibiotic-antimycotic (all from Life Technologies) and 5 ng/ml of carrier-free murine 
recombinant granulocyte and macrophage colony stimulating factor (GM-CSF) (R&D 
systems, Minneapolis, MN). Cell suspension was then plated on a poly-L-lysine (Sigma) 
coated plate and maintained at 37°C. The media was replaced every 3 days until the cells 
reached confluency. Microglia that formed a non-adherent, floating cell layer were collected, 
replated, and cultured for an extended period of time. Microglia were incubated for 3 days 
without GM-CSF before being re-plated for co-culture with MNs. Prior to analysis, 
microglia preparations were tested for the presence of CTLs and NK cells and were found to 
be devoid of them.
Mouse NPC isolation and differentiation into astrocytes
NPCs were isolated according to methods previously described29,62. Briefly, spinal cords 
were enzymatically dissociated in the same way as described for astrocytes. The cell 
suspension obtained was then mixed with an equal volume of isotonic Percoll (GE 
Healthcare) and was centrifuged at 20,000×g for 30 minutes at room temperature. Cells from 
the low-buoyancy fraction (5-10 ml above the red blood cell layer) were harvested, washed 
thoroughly with D-PBS/PSF (Invitrogen) and plated in 60 mm uncoated plates. Cells were 
grown in growth medium (DMEM/F12, Invitrogen) with 1% N2 supplement (Invitrogen), 20 
ng/ml of fibroblast growth factor-2 (FGF-2, Peprotech, Rocky Hill, NJ) and 20 ng/ml of 
endothelial growth factor (EGF, Peprotech). Cells were first grown as neurospheres and then 
were placed on a polyornithine-laminin (P/L)-coated plates, in which they grow as 
monolayer cultures. NPC cultures were found to be devoid of astrocytes, microglia, CTLs 
and NK cells contaminants. Once cultures were established, NPCs from wild-type and 
SOD1G93A mice were used to generate astrocytes by withdrawing growth factors and 
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supplementing the medium with 10% FBS (astrocyte media). The media was changed every 
2 days thereafter. Astrocytes were allowed to mature for 7 days prior to being used in the 
experiments described above. Highly enriched astrocyte cultures were obtained with no 
detectable levels of microglia, CTLs and NK cells.
Human post-mortem NPC derived astrocytes
Post-mortem spinal cords were obtained from the National Disease Research Interchange 
(NDRI, Philadelphia, PA) and from Dr. Fred Gage (Salk Institute, CA). Informed consent 
was obtained from all subjects. Receipt of human tissues was granted through Nationwide 
Children's Hospital Institutional Review Board (IRB08-00402) and all human samples were 
used in accordance with their approved protocols. Extensive phenotypic characterization of 
the cell lines used here has been previously described13,44. Cells were grown on laminin-
coated plates in astrocyte media supplemented 0.2% N2 supplement (Invitrogen). Media 
change occurred every 3 days, and cells were passaged when cultures reached 80% 
confluency. Human astrocyte cultures were found to be devoid of microglia, CTLs and NK 
cells.
iPSC generation
NPCs, expressing the MN Hb9::GFP reporter, obtained from wild-type and SOD1G93A mice 
were converted to iPSCs. As previously described, retrovirus encoding OCT3/4 and KLF4 
were sufficient to generate iPSC clones63,64. 20 viral particles per cell were needed to 
efficiently reprogram the cells. Cells were cultured in the presence of NPC media for four 
days followed by a change to mouse embryonic stem cell (mESC) media with DMEM 
(Millipore, Billerica, MA), supplemented with 18% ES FBS (Invitrogen), L-glutamine 
(2mM, Invitrogen), nonessential amino acids (1x, Millipore), antibiotic-antimycotic 
(Invitrogen), 2-mercaptoethanol (Sigma), and recombinant LIF (100U/ml, Millipore). iPSC 
clones were morphologically similar to mouse ESCs (HBG3 cells, Thomas Jessell, 
Columbia University) and were obtained within two weeks. A wide panel of markers was 
used to compare ESCs with the newly generated iPSC lines.
Mouse MN differentiation
Mouse ESCs or iPSCs expressing Hb9::GFP reporter were cultured on top of inactivated 
mouse fibroblasts (Millipore). MN differentiation was induced by plating 1-2 × 106 cells per 
10 cm dish in the presence of 2 μM retinoic acid (Sigma-Aldrich) and 2 μM purmorphamine 
(Calbiochem, Billerica, MA). After 5 days of differentiation, embryonic bodies were 
dissociated and sorted based on levels of GFP using a FACSVantage/DiVa sorter (BD 
Biosciences, Rockville, MD).
NPC differentiation into GABAergic neurons
Mouse NPCs were induced to differentiate into GABAergic neurons by supplementing 
growth medium with 0.1% FBS (Invitrogen), retinoic acid (1 μM, Sigma-Aldrich), and 
forskolin (5 μM, Sigma-Aldrich). Media were changed every day. Cultures were allowed to 
differentiate for 7 days prior to being used for experiments.
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Co-culture of mouse astrocytes with mouse MNs
Astrocytes were plated at the density of 35,000 cells per well in 96-well plates coated with 
laminin. After 48 hours, FACS sorted GFP+ MNs were plated on top of the astrocyte 
monolayer at a density of 10,000 cells per well. Co-cultures were performed in MN media 
composed of DMEM/F12 (Invitrogen) supplemented with 5% horse serum (Equitech Bio, 
Kerrville, TX), 2% N2 supplement (Invitrogen), 2% B27 supplement (Invitrogen), 10 ng/ml 
GDNF (Invitrogen), 10 ng/ml BDNF (Invitrogen), 10 ng/ml CNTF (Invitrogen). Half of the 
media was replaced every other day, with the addition of fresh growth factors.
Sustained expression of MHCI molecules in mouse MNs
To express histocompatibility 2 subclass MHCI in MNs, a previously described protocol was 
followed, with minor modifications65. Briefly, wild-type astrocytes were plated on a 
laminin-coated transwell (Corning, Lowell, MA) using MN media. After 24 hours, sorted 
GFP+ MNs were plated on a separate laminin-coated 96 well plate in media, conditioned by 
wild-type astrocytes. Four hours later, the transwell containing wild-type astrocytes was 
transferred into the MN plate, after verification that all MNs were fully attached and were 
starting to show neuritic extensions. The following day, the transwell of wild-type astrocytes 
was removed and the MNs were infected with Lv- H2k, H2k or H2l (40 viral particles per 
MN). Twelve hours post-infection, co-culture with wild-type astrocytes via transwell was 
resumed. After 72 hours, the transwell was removed and the co-culture experiments with 
wild-type and SOD1G93A astrocytes were initiated. Experiments were performed 
independently by two investigators.
Astrocyte conditioned media
Astrocyte conditioned medium was prepared by co-culturing mouse MNs and mouse 
astrocytes for 120 hours. After removal of cell debris by centrifugation (500 ×g for 10 min), 
medium was supplemented with GDNF, CNTF and BDNF. This medium was added to MNs 
cultures and cultures were evaluated after 24 hours.
Co-culture of human astrocytes with human MNs expressing HLA-F
MNs were obtained by differentiating human ES cell-derived MN progenitors (Lonza, 
Walkersville, MD) following the manufacturer's instructions. MN progenitors were plated at 
a density of 10,000 cells per well in a laminin coated 96-well plate. 48 hours after plating, 
the cells were infected with adenovirus encoding NGN2, ISL1, and LHX3 in order to 
enhance efficiency and shorten the time required for MN differentiation66. After 10 days of 
MN differentiation, MNs were infected with lentivirus to overexpress HLA-F (20 viral 
particles per MN). 3 days after, 10,000 human astrocytes were added to each well. Co-
cultures were allowed to continue for another 14 days, with half of the media being replaced 
every other day. Due to the limited number of MNs available at a time of study, astrocyted 
were randomly choosen and co-culture initiated.
Viral vectors
To knockdown H2kb levels in MNs or GABAergic neurons, sequences from the RNAi 
Consortium lentiviral shRNA library were screened and the sequence 5’ -
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TAAAGAGAACTGAGGGCTCTG -3’  was used. The sequence 5’ -
GGCGTAGATGTCCGATAAGAA-3’  was used for the scrambled shRNA control. 
Sequences were cloned into a lentiviral vectors. H2kb cDNA was purchased from Genecopia 
(Rockville, MD) and referred to as H2k. H2db cDNA (NM_010380.3) was purchased from 
Thermoscientific (Pittsburgh, PA) and referred to as H2k. H2-ld cDNA (NM_001267808.1) 
was synthesized by Genscript (Piscataway, NJ) referred to as H2l. To knockdown KIR3DL2 
in human ALS astrocytes, sequences from the RNAi Consortium lentiviral shRNA library 
were also screened and the sequence 5’ -TAAAGGAGAAAGAAGAGGAGG -3’  was used. 
The sequence 5’ -GGGAGAAAGAAGGAGGATAAA-3’  was used for the scrambled shRNA 
control. The HLA-F cDNA (NM_001098479.1) was purchased from Genecopia (Rockville). 
The production and purification of the lentivirus were performed as previously reported29.
MN cell viability
At various time points during the co-culture of mouse astrocytes and mouse MNs, cell 
survival, neuritic length and soma size of MNs were recorded using a fully automated IN 
CELL 6000 cell imager (GE Healthcare) as previously reported44. Images were processed 
with the Developer and Analyzer software package (GE Healthcare). Otherwise noted, 
images shown represent 120 hours post co-culture. All counts were performed in triplicate 
and repeated at least three times.
AAV9 injection in SOD1G93A mice
H2kb or H2db cDNA sequence used in our in vitro experiments was cloned into a AAV9 
vector that has been reported to transduce high levels of MNs in brain and spinal cords56,57. 
Self-complementary AAV9 encoding no transgene (AAV9-empty), or GFP (AAV9-GFP) or 
H2db (AAV9-H2k) or H2kb (AAV9-H2k) was produced by transient transfection procedures 
using a double-stranded AAV2-ITR-based CB vector, with a plasmid encoding Rep2Cap9 
sequence as previously described along with an adenoviral helper plasmid pHelper 
(Stratagene, Santa Clara, CA) in 293 cells. Injections of AAV9 were performed directly to 
the cerebral spinal fluid (CSF) at postnatal day 1 by direct injection into the lateral 
ventricles. Injection was performed with laser-pulled borosilicate glass needles (Sutter 
Instruments, Novato, CA, O.D.: 1.2 mm, I.D.: 0.69 mm 10 cm length) as previously 
described59. Animals received a total dose of 2.33×1013vg/kg in to 4 μl volume. To validate 
and minimize variability associated with the injection procedure, at least two fold (n = 24) of 
the minimum number of animals that the guidelines for preclinical animal research in 
ALS/MND suggests67 was used for our survival studies.
RNA isolation and RT-PCR
RNA was harvested using the RT2 q-PCR-grade RNA isolation kit (Qiagen, Frederick, MD) 
and total RNA was reverse transcribed with RT2 First Strand Kit (Qiagen) according to the 
manufacturer's instructions. After ensuring all cDNAs were devoid of genomic DNA 
contamination, mouse and human gene transcripts were amplified using gene-specific 
primers described in Supplementary Table 4. For detection of MHCI inhibitor receptor 
transcripts from the Ly49 gene and killer-cell immunoglobulin-like receptors (KIRs) 
families, astrocytes were prepared by co-culturing with mouse MNs and RT-PCR was 
performed using primer sets previously described68. Real-time quantitative PCR reactions 
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were performed using RT2 Real-Time SYBR Green/Rox Master Mix (Qiagen, Frederick, 
MD). Each sample was run in triplicate and relative concentration was calculated using the 
ddCt values normalized to endogenous actin transcript.
In situ hybridization
Spinal cords were removed from 60 day old wild-type mice and frozen in M1 embedding 
matrix (Shandon, Pittsburgh). The negative control, labeled with H2kbdb KO, was an 
H2kb−/−db−/− double knockout as previously described22. Twelve μm cryostat sections were 
obtained, affixed to slides, air-dried, and stored at −80°C. In situ hybridization was 
performed as previously described22,69. Briefly, slides were thawed and fixed in 4% 
paraformaldehyde before proteinase K (1 μg/ml) treatment. Slides were then acetylated and 
dehydrated in an ethanol series (50%, 75%, 2 X 95%, and 2X 100%). Labeled (?-35S-UTP) 
riboprobe was diluted to 0.75 × 107 cpm/ml in 1X Denhardt's solution with 50% deionized 
formamide, 10% dextran sulfate, 0.3 M NaCl, 10 mM Tris-HCl pH 8.0, and 1 mM EDTA 
pH 8.0; applied to sections; and then hybridization took place at 62°C for 12–18 h. After 
hybridization, coverslips were floated off in 4× SSC, and then treated with 50 μg/ml RNase 
A for 30 min at 37°C. Slides were washed with a series of SSC solutions, beginning at 2X 
and concluding with a high-stringency wash of 0.1X SSC (0.15 M sodium chloride/0.015 M 
sodium citrate, pH 7) at 60°C for 30 min. Finally, sections were dehydrated through an 
ethanol series and placed on film. After exposure to Kodak XAR-5 film at room 
temperature, sections were coated with NTB-2 emulsion and developed after 2–4 weeks.
The sequence of the H2db probe was: 3’ -
AGGTGGGCTACGTGGACGACGAGGAGTTCGTGCGCTTCGACAGCGACGCGGAGA 
ATCCGAGATATGAGCCGCGGGCGCCGTGGATGGAGCAGGAGGGGCCGGAGTATT 
GGGAGCGGGAAACACAGAAAGCCAAGGGCCAAGAGCAGTGGTTCCGAGTGAGC
C 
TGAGGAACCTGCTCGGCTACTACAACCAGAGCGCGGGCGGCTCTCACACACTCCA 
GCAGATGTCTGGCTGTGACTTGGGGTCGGACTGGCGCCTCCTCCGCGGGTACCT 
GCAGTTCGCCTATGAAGGCCGCGATTACATCGCCCTGAACGAGAACCCAC-5’ .
Adjacent sections were hybridized with sense and antisense probes. No specific 
hybridization was seen using sense probes.
Fixation and immunostaining
Cells were fixed with 4% paraformaldehyde (PFA) for 10 min. Mouse spinal cords were 
obtained by intracardiac perfusion with 4% PFA followed by 24 hours of post-fixation. 
Spinal cords were rinsed twice with 0.1 M sodium phosphate buffer and immersed in 30% 
sucrose for 2 days at 4°C or until the spinal cords sank to the bottom of the 50ml conical. 
Fixed spinal cords were embedded and sectioned using a vibratome (40 μm). For antigen 
detection using frozen sections, mouse spinal cord tissues were cut in 5- to 6-mm sections 
and embedded in Tissue-Tek OCT compound (Sakura Finetek) and frozen with dry ice. 
Tissues were then sectioned at 10 μm with a cryostat, collected directly on gelatinized 
objective slides and then stored at −20 °C before immunocytochemical analysis. Paraffin-
embedded human spinal cord tissues were obtained from NDRI and from Dr. Jonathan Glass 
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and Dr. Marla Gearing (Emory University, GA), which had obtained informed consent from 
all prospective donors. Tissues were sectioned at 10 μm and antigen retrieval methods were 
applied based on manufacturer's suggestions where primary antibodies were purchased. 
Staining of control and experimental groups was always performed in parallel. Antibodies 
used are listed in Supplementary Table 1. For most antigens, samples were first incubated 
for 1 hour in TBS containing 0.1% triton-X and 10% donkey serum, followed by incubation 
with the primary antibody for 48-72 hours at 4°C. For Ly49C/I staining, frozen sections 
previously prepared on slides were washed with TBS three times, then incubated for two 
hours in TBS containing 5% donkey serum, followed by incubation with primary antibody 
for 72 hours at 4°C. detection with cyanine dyes (Cy2, Cy3, and Cy5) labeled secondary 
antibodies used at the dilution of 1:250 (Jackson immunoresearch, West Grove, PA) was 
performed for 2 hours at room temperature.
MHCI staining was performed according to a previously described protocol, with minor 
modifications25,46. The antibody ER-HR52 recognizes histocompatibility 2 subclasses for 
mouse classical MHCI molecules (H2kbdb) and the antibody EMR8-5 recognizes all HLA-
A, B and C of the human classical MHCI molecules (HLA-ABC), therefore we refer to it in 
the text as MHCI. HLA-F expression was probed with a rabbit-anti-HLA-F antibody75,76. 
Membrane and cytoplasmic expression of HLA-F was interpreted as positive. Briefly, for in 
vitro MHCI labeling, cells on coverslips were fixed, blocked and incubated with primary and 
secondary antibodies without membrane permeabilization during the staining process. 
MHCI levels were obtained from randomly selected MNs using confocal microscope. MHCI 
fluorescence intensity values per MN were automatically measured using Adobe Photoshop 
CS5 extended version (Adobe, San Jose, CA) and were corrected to soma size and GFP 
expression of cells analyzed. For in vivo MHCI labelling, cell permeabilization was 
achieved using 0.05% triton-X for mouse spinal cord samples and 0.1% saponin for human 
spinal cord samples for 30 minutes at room temperature. Incubation with primary and 
secondary antibodies was performed in 10% donkey serum without any detergent. Detection 
of MHCI in paraffin embedded human tissue was achieved with 3,3’ -diaminobensidine 
staining by using the ABC and VectorRed Kit protocols (Vector Laboratories, Burlingame, 
CA). Tissues were counterstained with Hematoxylin QS solution (Vector Laboratories). 
Fluorescence images were captured on a laser scanning confocal microscope (Carl Zeiss 
Microscopy, Thornwood, NY) and 3,3’ -diaminobensidine stained images were captured with 
the Zeiss Axioscope. Evaluation of MHCI levels in MNs were performed by an operator 
blinded to the identity of sample been evaluated.
Statistical analysis
Statistical analysis was performed using Graph Pad Prism 6 software (La Jolla). Depending 
on the number of variables and time-points in each experiment, statistical analysis of mean 
differences between groups was performed by either Student's t-test or multiway ANOVA 
followed by a Bonferroni post hoc analysis. Kaplan-Meier survival analyses were analyzed 
by the log-rank test. Comparison of mean survival, disease onset and progression were 
analyzed by the unpaired t test. Specific statistical tests, P values and sample size are 
indicated in figure legends.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. MHCI expression is reduced on spinal MNs in end-stage ALS
(a) Representative immunofluorescence images (from three images evaluated) showing 
MHCI (H2db/H2kb) expression in MNs at 30 and 125 days in SOD1G93A mice. (b) Percent 
of MHCI positive lumbar spinal cord MNs in SOD1G93A and control mice evaluated as 
shown in (a) For each group, two animals were used and MNs counts were pulled together. 
321, 216, 216, 154 MNs were counted in graph columns 1 through 4. (c) 
Immunohistochemical analysis of MHCI (HLA-ABC) expression in spinal MNs of 
individuals with ALS post-mortem. Green arrowheads point to MNs. (d) Percent of MHCI 
positive MNs in the spinal cords of individuals with ALS individuals and controls 
determined as shown in (c). For analysis two non-ALS, two FALS and 6 SALS individuals 
were analyzed. 50, 60, 35, 51, 71, 87, 45, 46, 68 and 22 of MNs were counted in graph 
columns 1 through 10. WT, wild-type mouse. SOD1, SOD1G93A mouse. Scale bars 20 μm.
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Figure 2. ALS astrocytes induce down-regulation of MHCI expression in MNs
(a,b) Representative immunofluorescence images (of three independent experiments) 
showing MHCI (H2db/H2kb) expression in MNs cultured in the presence of either wild type 
or SOD1G93A microglia for 72 hours (a) and measurement of their MHCI expression relative 
to levels found in MNs cultured with wild type microglia for 24h (b). (c,d) Representative 
immunofluorescence images (of three independent experiments) showing MHCI (H2db/
H2kb) expression in MNs cultured in the presence of either wild type or SOD1G93A 
astrocytes during a 120 hours period (c) and measurement of their MHCI expression relative 
to levels found in MNs cultured with wild type astrocytes for 24h (d). Experiments were 
made in triplicate. Levels of MHCI are expressed as mean fluorescence intensity (MFI) 
found in MNs. Error bars represent s.e.m.. Each dot in graphs (b and d) represents MHCI 
level found per MN (One-Way ANOVA, *P<0.05; ***P<0.001; n.s., non-significant 
P≥0.05). WT, wild-type mouse. SOD1, SOD1G93A mouse. Scale bars 10 μm.
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Figure 3. H2kb expression protects MNs from ALS astrocyte-induced toxicity and delays disease 
progression in SOD1G93A mice
(a) Representative immunofluorescence images (of three independent experiments) of MNs 
expressing either RFP or H2k and cultured in the presence of wild type or SOD1G93A 
astrocytes for 120 hours. Scale bar 100 μm. (b) Survival of MNs expressing either, RFP, 
H2k, H2k or H2l and cultured in the presence of wild type or SOD1G93A astrocytes for 120 
hours. Data shown is a representative of three independent experiments and is displayed as 
the mean ± s.e.m of counts three replicates (****P<0.0001; n.s., non-significant, one-Way 
ANOVA). (c) Kaplan-Meier survival curve of female SOD1G93A mice treated with AAV9-
H2k (n = 28), AAV9-H2k (n = 14) or AAV9-empty controls (n = 26). Mean survival, AAV9-
H2k 156.9 ± 2.6, AAV9-H2k 139.2 ± 1.4, AAV-9-empty 135.5 ± 1.6 days, mean ± s.e.m, P< 
0.0001, unpaired t-test. (d,e) Age of onset observed in AAV9 treated SOD1G93A mice and 
displayed by the Kaplan-Meier curve (d) and the mean age of onset (e). AAV9-H2k 103.3 
± 2.0, AAV9-H2k 103.1 ± 1.2 days, AAV-9-empty 99.73 ± 1.2, mean ± s.e.m, P=0.1, 
unpaired t- test. (f) Mean disease progression observed in AAV9 treated SOD1G93A mice. 
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AAV9-H2k, 52.7 ± 2.6; AAV9-H2k, 34.62 ± 2.2; AAV9-empty 34.1 ± 1.8 days, mean ± 
s.e.m, P<0.0001, unpaired t-test. (g) Rotarod performance of AAV9-H2k treated SOD1G93A 
mice compared with age-matched controls, mean ± s.e.m, *P<0.05; **P<0.01; ***P<0.005, 
unpaired t- test. WT, wild-type. SOD1, SOD1G93A. Ast, astrocytes.
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Figure 4. ALS astrocytes express MHCI inhibitory receptors
(a-e) Evaluation of the expression of MHCI inhibitory receptors found in SOD1G93A mice 
spinal cord at disease end-stage (a-c) or astrocytes lines (d-e), by RNA analysis (a,d) or 
immunohistochemistry analysis (b,c,e). (f-h) Expression of the MHCI inhibitory receptor 
KIR3DL2 in human ALS astrocytes cell lines as determined by RNA analysis (f) and in 
sections of spinal cord from SALS post–mortem tissue (g-h). Data presented in (a-h) is a 
representative of finding form three independent experiments. WT, wild-type. SOD1, 
SOD1G93A. Scale bars 50 μm (b), 200 μm (e, g), 10 μm (c), 5 μm (h).
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Figure 5. HLA-F expression protects human MNs from ALS astrocyte-induced toxicity
(a) Representative images (from three independent experiments) of immunohistochemistry 
analysis performed in human spinal cord tissue probing for HLA-F expression. Green 
arrowheads point to MNs. HLA-F was visualized by 3,3'-Diaminobenzidine (DAB) staining. 
(b) Percent of HLA-F positive MNs found in human spinal cords of ALS individuals and 
control determined as shown in (a). For columns 1 through 5, the total number of MNs was 
62, 58, 54, 26 and 42, respectively. Scale bars 20 μm. Number at the bottom of the columns 
represent subject ID number. (c) Microscope images of human ESC derived MNs used to 
evaluate morphology and expression of prototypic MN markers. (d) RNA (upper panel) and 
immunocytochemistry analysis (lower panel) of lentivirus infected cells displaying HLA-F 
and eGFP expression in human MNs. (e) Representative images (from three independent 
experiments) of human MNs expressing HLA-F and co-cultured with FALS and SALS 
astrocyte visualized by ChAT staining. (f) Quantification of the number of surviving MNs as 
shown in (e). Dotted line represents average MN counts when co-cultured with non-ALS 
controls. Data shows a representative of three independent experiments and is displayed as 
the mean ± s.e.m counts of triplicates. (One-Way ANOVA, *P< 0.05; **P< 0.01; 
***P<0.001; ns, non-significant P≥0.5). Scale bars 20 μm (a), 50 μm (c-d), 100 μm (e).
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